ساخت اکانت کاربری رایگان

مقالات پذیرفته شده کنگره

  • صفحه نخست
  • مقالات پذیرفته شده اولین کنگره بین المللی ژنتیک سرطان
بازنشر

  • Evaluation of a Recombinant HPV Based Therapeutic Vaccine in a Murine Model of Cervical Cancer

  • Bahar Eslami,1,* Diana Shahbazi,2 Mahdieh Moradian,3 Maryam Pourjafar,4 Armita Shiri,5 Saber Abaszadeh,6
    1. student research committee school of medicine guilan university of Medical sciences, Rasht, Iran
    2. student research committee school of medicine guilan university of Medical sciences, Rasht, Iran
    3. student research committee school of medicine guilan university of Medical sciences, Rasht, Iran
    4. student research committee school of medicine guilan university of Medical sciences, Rasht, Iran
    5. student research committee school of medicine guilan university of Medical sciences, Rasht, Iran
    6. Student Research Committee, Lorestan University of Medical Sciences, Khorramabad, Iran.


  • Introduction: Background: Human papillomavirus (HPV) infection is the primary cause of over 95% of cervical cancer cases, with high-risk types HPV 16 and HPV 18 responsible for approximately 70% of these malignancies. Although prophylactic vaccines are available, there is no definitive treatment for women with persistent infection and precancerous lesions.
  • Methods: Methods: This study evaluated the immunogenicity of a recombinant therapeutic vaccine based on the HPV 16 E7 protein in a BALB/c mouse model. The recombinant E7 protein was expressed in E. coli and purified. Thirty female mice were divided into five groups (n=6): (1) E7+CFA, (2) E7+Alum, (3) E7 alone, (4) PBS (negative control), and (5) positive control. Three subcutaneous doses (50 µg) were administered on days 0, 14, and 28. Humoral responses were assessed by ELISA, and cellular responses by ELISpot and flow cytometry.
  • Results: Results: The E7+CFA group showed the highest specific anti E7 IgG titer (11,200 ± 1,300 vs. controls, p<0.001). The IgG2a/IgG1 ratio was 2.8 ± 0.4, indicating Th1 dominant response. IFN γ secreting cells (180 ± 20 per 10⁶ cells) were significantly higher than controls (p<0.001).
  • Conclusion: Conclusion: The recombinant E7 vaccine, especially when formulated with CFA, induces robust Th1 biased humoral and cellular immune responses, supporting its potential as a candidate for cervical cancer immunotherapy.
  • Keywords: HPV 16, E7 protein, Therapeutic vaccine, Cervical cancer, Immunogenicity, Th1 immune response, BALB/

به خانواده بزرگ کنسر ژنتیکس و ژنومیکس سرطان بپیوندید!

ایجاد حساب کاربری رایگان